Difference between revisions of "Part:BBa K4593002:Design"

(→‎Design Notes)
(→‎References)
 
(4 intermediate revisions by the same user not shown)
Line 7: Line 7:
  
 
===Design Notes===
 
===Design Notes===
−
The sequence does not contain a start codon and must be cloned to vectors used for protein purification (such as pET-28 in our project) before being used.
+
The sequence is codon optimized for expression in E. coli.
  
 
===Source===
 
===Source===
  
−
Hybrid endolysin from domains of 12 natural staphylococcal endolysins.
+
Hybrid endolysin with CBD of LysPALS1 and EAD of LysSA12.
  
 
===References===
 
===References===
−
Lee, Chanyoung, et al. “Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus Aureus through Domain Shuffling.” ACS Infectious Diseases, vol. 7, no. 8, 28 May 2021, pp. 2081–2092.
+
[1] Lee, Chanyoung, et al. “Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus Aureus through Domain Shuffling.” ACS Infectious Diseases, vol. 7, no. 8, 28 May 2021, pp. 2081–2092.
−
https://doi.org/10.1021/acsinfecdis.0c00812.
+
https://doi.org/10.1021/acsinfecdis.0c00812

Latest revision as of 23:40, 8 October 2023


ClyC


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 681
    Illegal AgeI site found at 550
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

The sequence is codon optimized for expression in E. coli.

Source

Hybrid endolysin with CBD of LysPALS1 and EAD of LysSA12.

References

[1] Lee, Chanyoung, et al. “Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus Aureus through Domain Shuffling.” ACS Infectious Diseases, vol. 7, no. 8, 28 May 2021, pp. 2081–2092. https://doi.org/10.1021/acsinfecdis.0c00812